This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

proofread

Research team develops nanoparticle-based sonodynamic therapy for H. pylori infection

Research team develops nanoparticle-based sonodynamic therapy for H. pylori infection
In vitro performances of the model nanosonosensitizers. Credit: Nature Communications (2024). DOI: 10.1038/s41467-024-45156-8

Helicobacter pylori (H. pylori) is a common pathogen that can be transmitted from person to person. Long-term H. pylori infection has been recognized as a Class I human carcinogen. Currently, the standard clinical treatments for H. pylori infection (i.e., triple and quadruple therapy) rely on oral antibiotics to clear H. pylori from the stomach.

However, in H. pylori has led to an increase in the failure and recurrence rates of clinical treatments over the years. Oral antibiotics can lead to an imbalance of the intestinal flora. In addition, clinical standard therapies such as triple therapy ignore vacuolar toxin A, a vital virulence factor in H. pylori infection.

A research team led by Prof. Yang Lihua from Hefei National Research Center for Physical Sciences at the Microscale, the University of Science and Technology of China (USTC) of the Chinese Academy of Sciences, has developed a nanoparticle-based sonodynamic therapy to reduce H. pylori infection in mouse without disrupting . The study was published in Nature Communications.

The nanoparticles that mediate this sonodynamic therapy have been approved for clinical use and have dual efficacy in this therapy. The therapy neutralizes vacuolating cytotoxin A, a key virulence factor secreted by H. pylori, even without the presence of ultrasound.

When combined with an ultrasound exposure dosage that meets the criteria for the use of ultrasound , it kills H. pylori through the production of reactive oxygen species, offering the possibility of addressing antimicrobial drug resistance.

Ultrasonic power therapy for helicobacter pylori infection
Up- and down-regulated human gut commensal bacterial strains after antibiotic-based H. pylori eradication therapies. Each circle, whether solid black or hollow white, represents a gut commensal bacterial strain that has been reported to experience a change in abundance after antibiotic-based H. pylori eradication treatment, and the number enclosed within the circle corresponds to the relevant reference, which can be located in the reference list provided at the bottom right. A solid black circle represents a commensal bacterial strain for which the relevant reference did not report the P value pertaining to its change of abundance in the host gut after antibiotic-based H. pylori eradication treatment. The hollow white circles represent commensal bacterial strains, for which the relevant references have provided P values pertaining to their changes of abundance in the host gut after antibiotic-based treatment for H. pylori eradication, and the sizes of these white circles progressing from smallest through medium to largest correspond to P values of <0.05, <0.01, and <0.001, respectively. Credit: Nature Communications (2024). DOI: 10.1038/s41467-024-45156-8

In female mouse models infected with H. pylori, this sonodynamic therapy worked comparably to the standard triple therapy when it came to lower gastric infections. Unlike antibiotic-based clinical standard therapies, it did not have a significant negative impact on the intestinal microbiota, except for an upregulation on mouse intestinal levels of Lactobacillus, a beneficial bacterium widely used in yogurt and probiotic products.

Besides, it did not adversely affect liver or or the overall health of the mice within 48 hours of treatment administration, consistent with the safety standard of triple therapy.

However, a significant difference in the levels of interleukin-1 receptor antagonist (IL-1RA), a protein that plays a key anti-inflammatory role in a variety of diseases, was observed at 12 weeks post-treatment: the up-regulated serum IL-1RA levels in the mice, whereas the sonodynamic therapy did not.

This study presents a promising alternative to the current antibiotic-based therapies for H. pylori infection, offering a reduced risk of antimicrobial resistance and minimal disturbance to the gut microbiota.

More information: Tao Liu et al, A nanoparticle-based sonodynamic therapy reduces Helicobacter pylori infection in mouse without disrupting gut microbiota, Nature Communications (2024). DOI: 10.1038/s41467-024-45156-8

Provided by University of Science and Technology of China

Citation: Research team develops nanoparticle-based sonodynamic therapy for H. pylori infection (2024, March 1) retrieved 15 April 2024 from https://phys.org/news/2024-03-team-nanoparticle-based-sonodynamic-therapy.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Three-drug combination, RHB-105, effectively eradicates H pylori infection in adults

37 shares

Feedback to editors